Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines

Sakai, Toshinori; Eskander, Ramez N.; Guo, Yi; Kim, Kap Jung; Mefford, Jason; Hopkins, Justin; Bhatia, Nitin; Zi, Xiaolin; Hoang, Bang H.

doi:10.1002/jor.22050

Cited by 55 publications

(38 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, survivin has demonstrated the ability to prevent the release of apoptosis-induced factor from the mitochondrial intermembrane space, protecting cells against apoptotic death (19,21,22). Futhermore, survivin also suppresses apoptosis via inhibition of the pathway of death receptors and downstream tumor necrosis factor-related apoptosis-inducing ligand (13,18,23,24). The present study was limited to examination of the total apoptosis profile and the protein expression levels of procaspase-3, a principle 'executor', committing cells to death via the intrinsic apoptosis pathway (19,25).…”

Section: Discussionmentioning

confidence: 99%

Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells

et al. 2015

View full text Add to dashboard Cite

Abstract. Survivin overactivation is a frequent event in human hepatocellular carcinoma (HCC), due to its function in the induction of hepatocyte proliferation and apoptotic dysfunction. Recently, a novel survivin inhibitor named YM155, has demonstrated broad antitumor effects against various malignant tumors. Therefore, the present study aimed to explore how this agent may impact on HCC and elucidate its underlying mechanism of action. Immunohistochemical analysis was performed on 8 specimens of human HCC, to assess the protein expression of survivin and phosphorylated retinoblastoma tumor suppressor (p-Rb). In addition, in vitro, HepG2 and Huh7 human HCC cell lines were exposed to 100 µM YM155 for up to 72 h and the cell viability was subsequently determined using MTT assay. Furthermore, the apoptotic status of YM155-treated HCC cells was investigated by flow cytometry, and the protein levels of survivin, procaspase-3 and p-Rb in YM155-treated HCC cells were assessed by immunoblotting analysis. The results demonstrated that HCC specimens expressed high levels of survivin and p-Rb protein compared with those of adjacent noncancerous liver tissues. In vitro, YM155 significantly induced HCC cell apoptosis and growth arrest. At the protein level, YM155 markedly inhibited survivin and p-Rb expression, and elevated procaspase-3. YM155 demonstrated significant antitumor effects on HCC cells in the present study. These effects were associated with its anti-proliferative and apoptosis-induction activities. YM155 requires further investigation as a novel agent for potential use as a therapeutic strategy for the treatment of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It was observed that licochalcone A suppressed the growth of all the three tested bladder cancer cell lines in a dose-dependent manner (Figure 1). ERK 1/2 has been reported to be involved in drug resistance [11][12][13][14][15][16][17]. …”

Section: Effect Of Licochalcone a On Bladder Cancer Cell Growth And Ementioning

confidence: 99%

“…They exhibit anti-inflammatory [9], anti-invasive [10], anti-tumour [11] and antibacterial [12] properties. Chalcone treatment causes induction of apoptosis and alters mitochondrial membrane potential in various types of cancers [13]. Licochalcone A (LA), an oxygenated chalcone was isolated from the roots of the Chinese liquorice (Glycyrrhiza uralensis).…”

Section: Introductionmentioning

confidence: 99%

Licochalcone A exerts antitumor activity in bladder cancer cell lines and mice models

Zhang¹,

Huang²,

Liu³

et al. 2016

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the effect of licochalcone A (LA) on the inhibition of cell proliferation and ERK1/2 phosphorylation in bladder carcinoma cell lines. Methods:Cell viability was investigated using 3- (4,5-dimethylthiazol-2-yl In the mouse model, licochalcone A treatment via intraperitoneal (ip) administration induced a significant decrease in the level of regulatory T cells (Tregs). Comparison of the mouse interferon-α (IFN-α)-treated and LA-treated groups revealed that LA treatment caused enhancement of cytotoxic T lymphocyte (CTL) activity similar to that of IFN-α. Administration of UM-UC-3 cells in C3H/

show abstract

“…In vitro kísérletek azt mutatták, hogy a fl awokawain B (új chalcone a kavakivonatból) potenciálisan gátolja az SS-sejtvonalat és apoptózist indukál [45]. Az epigallocatechin-3-gallate hatékony sejtnövekedést gátló szer SSsejtvonalakon [46].…”

Section: Kísérleti Szerekunclassified

A sarcoma synoviale kezelési lehetőségei

Deme¹,

Telekes

2015

Orvosi Hetilap

View full text Add to dashboard Cite

A sarcoma synoviale a lágyrész-sarcomák 5-10%-ában, az összes malignus daganatok 0,05-0,1%-ában fordul elő. Főként a végtagokon keletkezik, azonban bárhol kialakulhat. A betegek 50%-ában 3-5 éven belül metasztázisok jelennek meg (tüdő, nyirokcsomó, csont), sőt akár 20 év elteltével is számítani lehet a sarcoma synoviale kiújulására. Az 5 éves teljes túlélés lokalizált betegség esetén 76%, metasztatikus esetben 10%. Az életkor, daganatméret, szö-vettani altípus és a radioterápia megtörténte befolyásolja a prognózist. Az adjuváns kemoterápia szerepe nem bizonyított. Számos klinikai vizsgálat van folyamatban a lokálisan előrehaladott, relaptálódott/refrakter és metasztatikus sarcoma synoviale kezelésére. A sarcoma synoviale biológiai viselkedésének jobb megértésével a célzott kezelés és a konvencionális terápia kombinációja válhat a jövő útjává. Orv. Hetil., 2015, 156(22), 875-880.Kulcsszavak: sarcoma synoviale, kemoterápia, radioterápia, célzott kezelés Therapeutic options for synovial sarcomaSynovial sarcomas account for approximately 5 to 10% of soft tissue sarcomas and 0.05 to 0.1% of all malignant neoplasms. They predominantly affect the extremities but can occur in any part of the body. More than 50% of the patients are expected to develop metastatic disease within 3-5 years. In some patients disease recurrence may develop after 20 years. The 5-year overall survival rate is 10% for patients with metastatic disease and 76% for patients with localized one. Age, tumour size, histological subtype, and adjuvant radiotherapy infl uence prognosis. The role of adjuvant chemotherapy has not been proven yet. There are several ongoing clinical trials to determine the effi cacy of active agents used for therapy of locally advanced, relapsed/refractory or metastatic disease. Better understanding of the biological behaviour of synovial sarcomas would provide the future way for the targeted therapy in combination with conventional treatments. Rövidítések CCND1 = ciklin D1; CR = komplett remisszió; DRFS = távoli kiújulásmentes túlélés; EFS = eseménymentes (gyógyszertoxi-citás, -intolerancia, egyéb) túlélés; EpSSG = European Pediatric Soft Tissue Sarcoma Group; HDAC = hiszton-deacetiláz; IGF-1R = inzulinszerű növekedési faktor receptor-1; KT = kemoterápia; LRFS = lokális kiújulásmentes túlélés; MD = metasztatikus betegség; MFS = áttétmentes túlélés; OS = teljes túlélés; PD = progresszív betegség; PFS = progressziómentes túlélés; PR = parciális remisszió; RT = radioterápia; SD = stabil betegség; SEER = Surveillance, Epidemiology, and End Results; SS = sarcoma synoviale A sarcoma synoviale (SS) a ritka malignitások közé tartozik. A malignus daganatok 0,05-0,1%-át és a lágyrész-sarcomák 5-10%-át alkotja [1,2]. Az SS leggyakrabban a serdülőkorúak és fi atal felnőttek 15-40 éves korosztá-lyát érinti, azonban előfordulhat 10 éven aluli gyermekekben, sőt újszülöttekben is [3]. Prognosztikai faktorokTöbb munkacsoport vizsgálta az SS-ben szenvedő pá-ciensek túlélését befolyásoló prognosztikai faktorokat, amelyek közül az 5 cm vagy ann...

show abstract

Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines

Cited by 55 publications

References 17 publications

Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells

Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells

Licochalcone A exerts antitumor activity in bladder cancer cell lines and mice models

A sarcoma synoviale kezelési lehetőségei

Contact Info

Product

Resources

About